Helix BioPharma (OTCMKTS:HBPCF) Posts Quarterly Earnings Results

Helix BioPharma (OTCMKTS:HBPCF) released its earnings results on Monday. The company reported ($0.02) EPS for the quarter, Zacks reports.

Helix BioPharma Stock Performance

HBPCF remained flat at $0.60 on Monday. The firm’s 50 day moving average is $0.56 and its 200-day moving average is $0.49. Helix BioPharma has a 52-week low of $0.59 and a 52-week high of $0.60. The firm has a market capitalization of $31.81 million, a P/E ratio of -6.00 and a beta of -0.22.

Helix BioPharma Company Profile

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.